A Phase II, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682 + MK-8408 in Subjects With Chronic HCV Genotype 1, 2, 3, 4, 5 or 6 Infection

Trial Profile

A Phase II, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682 + MK-8408 in Subjects With Chronic HCV Genotype 1, 2, 3, 4, 5 or 6 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Ruzasvir (Primary) ; Uprifosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms C-BREEZE 1
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 21 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 31 Oct 2017 Planned End Date changed from 7 Apr 2020 to 17 Nov 2017.
    • 24 Oct 2017 Results (n=149) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top